Key Points
- Director Raymond Debbane bought 100,000 shares on Feb. 23 at $1.47 (total $147,000) and had earlier acquired 100,000 shares on Feb. 20 and 50,000 on Feb. 19, bringing his recent purchases to 250,000 shares and raising his stake to 1,904,186 shares — a 5.54% ownership increase.
- LXRX traded down 2.3% to $1.47 with a market cap of $532.48M and a negative P/E (-7.71); institutional investors own 74.7% and analysts’ consensus is a Hold with an average target of $3.23.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) Director Raymond Debbane purchased 100,000 shares of the firm's stock in a transaction that occurred on Monday, February 23rd. The stock was purchased at an average price of $1.47 per share, with a total value of $147,000.00. Following the purchase, the director directly owned 1,904,186 shares of the company's stock, valued at $2,799,153.42. The trade was a 5.54% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Raymond Debbane also recently made the following trade(s):
- On Friday, February 20th, Raymond Debbane acquired 100,000 shares of Lexicon Pharmaceuticals stock. The stock was purchased at an average cost of $1.48 per share, for a total transaction of $148,000.00.
- On Thursday, February 19th, Raymond Debbane acquired 50,000 shares of Lexicon Pharmaceuticals stock. The stock was purchased at an average price of $1.44 per share, for a total transaction of $72,000.00.
Lexicon Pharmaceuticals Stock Down 2.3%
Shares of LXRX stock traded down $0.04 on Thursday, reaching $1.47. 777,761 shares of the stock were exchanged, compared to its average volume of 2,953,029. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47. The business's 50 day moving average price is $1.31 and its 200 day moving average price is $1.31. The company has a market capitalization of $532.48 million, a price-to-earnings ratio of -7.71 and a beta of 0.98. Lexicon Pharmaceuticals, Inc. has a twelve month low of $0.28 and a twelve month high of $1.83.
Hedge Funds Weigh In On Lexicon Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the stock. Security National Bank of Sioux City Iowa IA purchased a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $31,000. Hudson Bay Capital Management LP purchased a new position in Lexicon Pharmaceuticals in the second quarter worth $26,000. Leonteq Securities AG purchased a new stake in Lexicon Pharmaceuticals during the fourth quarter worth about $34,000. Vermillion & White Wealth Management Group LLC boosted its stake in shares of Lexicon Pharmaceuticals by 400.0% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company's stock worth $44,000 after acquiring an additional 26,000 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $39,000. Institutional investors and hedge funds own 74.70% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen lowered Lexicon Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, November 15th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Lexicon Pharmaceuticals currently has an average rating of "Hold" and an average target price of $3.23.
Check Out Our Latest Research Report on LXRX
Lexicon Pharmaceuticals Company Profile
(
Get Free Report)
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon's approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.
The company's most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
